- Former Inspector General, US Dept. of Health and Human
Services
- Former Assistant US Attorney for the Eastern District of
Virginia
- Nationally recognized attorney in highly regulated
industries; healthcare specialist
RADNOR,
Pa., Dec. 27, 2023 /PRNewswire/ -- NRx
Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the
"Company"), a clinical-stage biopharmaceutical company today
announced that Janet Rehnquist has
been elected to the Company's Board of Directors where she will
chair the compliance and the nominating committees.
Ms. Rehnquist is an experienced healthcare lawyer who
specializes in reimbursement and compliance matters. Previously,
she served as Inspector General of the US Department of Health and
Human Services and, before that as Assistant US Attorney for the
Eastern District of Virginia.
"I am excited to join the Board of NRx Pharmaceuticals - a
biotech company focused on developing drug treatments to address
urgent unmet medical needs in CNS and mental health, particularly
suicidal depression. As I shared with the Company's shareholders, I
have watched loved ones battle this challenge and I realize the
potential of a breakthrough drug for suicidal depression to benefit
the lives of millions. I look forward to bringing my passion for
healthcare to the mission of improving lives, " said Ms.
Rehnquist.
"We at NRx are thrilled to welcome someone with Janet's
distinguished record and unquestioned integrity to the Board of NRx
Pharmaceuticals" said Jonathan
Javitt, MD MPH, Founder and Chief Scientist of NRx
Pharmaceuticals. "Janet's talents as a seasoned attorney and
Board member, along with vast healthcare compliance experience
align perfectly with our aim to bring a lifesaving drug for
suicidal depression to patients in the near future. We look forward
to working together to brighten the reality for patients whose only
approved treatment today is hospitalization and electroshock
therapy."
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical
company developing therapeutics based on its NMDA platform for the
treatment of central nervous system disorders, specifically
suicidal bipolar depression, chronic pain and PTSD. The Company is
developing NRX-101, an FDA-designated investigational Breakthrough
Therapy for suicidal treatment-resistant bipolar depression and
chronic pain. NRx has partnered with Alvogen Pharmaceuticals around
the development and marketing of NRX-101 for the treatment of
suicidal bipolar depression. NRX-101 additionally has potential to
act as a non-opioid treatment for chronic pain.
NRx has recently announced plans to submit a New Drug
Application for ketamine in the treatment of suicidal depression,
based on results of well-controlled clinical trials conducted under
the auspices of the US National Institutes of Health and newly
obtained data from French health authorities, licensed under a data
sharing agreement. NRx was awarded Fast Track Designation for
development of ketamine (NRX-100) by the US FDA as part of a
protocol to treat patients with acute suicidality.
Cautionary Note Regarding Forward-Looking Statements
This press release includes "forward-looking statements" within
the meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995, which may include, but
are not limited to, statements regarding our financial outlook,
product development, business prospects, and market and industry
trends and conditions, as well as the Company's strategies, plans,
objectives, and goals. These forward-looking statements are based
on current beliefs, expectations, estimates, forecasts, and
projections of, as well as assumptions made by, and information
currently available to, the Company's management. Actual results
could differ materially from those contemplated by the
forward-looking statements. A discussion of these and other
factors, including risks and uncertainties with respect to the
Company, is set forth in the Company's filings with the Securities
and Exchange Commission, including its Annual Report on Form 10-K,
as may be supplemented, or amended by the Company's Quarterly
Reports on Form 10-Q. Given these risks, uncertainties, and
factors, you are cautioned not to place undue reliance on such
forward-looking statements, which are qualified in their entirety
by these cautionary statements.
The Company assumes no obligation to revise any forward-looking
statement, whether as a result of new information, future events or
otherwise. Accordingly, you should not place reliance on any
forward-looking statement, and all forward-looking statements are
herein qualified by reference to the cautionary statements set
forth above.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-announces-the-election-of-janet-rehnquist-to-its-board-of-directors-302022640.html
SOURCE NRx Pharmaceuticals, Inc.